Akoya Biosciences Inc represents values of innovation, collaboration, and precision in the area of spatial biology. As a leading provider of high-dimensional biomarker analysis solutions, the company is dedicated to enabling researchers to gain new insights into complex diseases and develop effective therapies. Akoya Biosciences emphasizes the importance of collaboration with scientific and industry partners to advance scientific understanding and improve patient outcomes. With a corporate philosophy centered around empowering researchers, Akoya Biosciences strives to provide cutting-edge technologies and services that unlock the full potential of spatial biology research.

Akoya Biosciences Inc is primarily present in the United States.

Akoya Biosciences Inc has achieved significant milestones in the field of life sciences and drug development. The company successfully developed and commercialized the CODEX® platform, an innovative technology for high-parameter spatial biology. Moreover, Akoya Biosciences Inc secured substantial funding through multiple financing rounds, allowing them to expand their product portfolio and accelerate research and development efforts. They have established strategic collaborations with leading pharmaceutical companies to advance precision medicine and improve patient outcomes. The company's commitment to innovation and scientific excellence has positioned them as a key player in the field, driving advancements in spatial biology and transforming the future of research and diagnostics.

Akoya Biosciences Inc, founded in 2015, is a leading life sciences company revolutionizing spatial biology with its innovative technologies. The company specializes in developing multiplexed imaging tools, including the CODEX® system, which enables detailed analysis of biomarkers within the context of tissue biology. By providing high-resolution spatial data, Akoya Biosciences helps researchers gain deeper insights into complex diseases and accelerate drug discovery. With its cutting-edge solutions, Akoya Biosciences has become a trusted partner for academic institutions, pharmaceutical companies, and research organizations worldwide. Combining expertise in biology, chemistry, and engineering, Akoya Biosciences is committed to driving scientific discovery and advancing precision medicine.

The main competitors of Akoya Biosciences Inc in the market include companies such as NanoString Technologies, PerkinElmer, and Visiopharm. These companies also operate in the field of biomarker analysis and are known for their advancements in multiplexed imaging and spatial biology solutions. Despite facing competition, Akoya Biosciences Inc stands out due to its innovative CODEX® technology, which allows for highly multiplexed imaging of tissues at single-cell resolution. This unique offering differentiates Akoya Biosciences Inc and positions it as a key player in the market.

Akoya Biosciences Inc is primarily active in the life sciences and healthcare industries. As a leading provider of multiplexed immunohistochemistry (mIHC) and imaging solutions, Akoya Biosciences enables researchers and scientists to better understand diseases and develop targeted therapies. With its innovative CODEX® and Phenoptics™ platforms, the company empowers precision medicine and personalized healthcare by enabling spatial and molecular profiling of complex biological systems. Akoya Biosciences' technologies are utilized by pharmaceutical companies, academic researchers, and clinical laboratories to advance scientific and medical knowledge in fields such as cancer research, neuroscience, and immunology.

The business model of Akoya Biosciences Inc revolves around providing innovative solutions for immuno-oncology research. The company specializes in developing advanced multiplexed immunohistochemistry (mIHC) and imaging solutions that allow researchers to analyze multiple biomarkers within a single tissue section. Akoya Biosciences Inc offers the CODEX® system, a high-throughput imaging platform, along with comprehensive software for data analysis. This enables researchers to gain deeper insights into the tumor microenvironment, accelerating drug development and personalized medicine. Akoya Biosciences Inc's business model focuses on delivering cutting-edge technology and services to advance the understanding and treatment of cancer.

Akoya Biosciences KGV ir -1,77.

Akoya Biosciences KUV ir 1,14.

AlleAktien kvalitātes vērtējums Akoya Biosciences ir 3/10.

gaidāmā Akoya Biosciences apgrozījums ir 85,36 milj. USD.

gaidāmā Akoya Biosciences peļņa ir -54,97 milj. USD.

Akoya Biosciences Inc is a leading biotechnology company that aims to support the discovery and development of new drugs and therapies for various diseases. The company offers innovative and advanced technologies for the study of cells and tissues, allowing researchers and scientists to better understand and target diseases. The business model of Akoya Biosciences Inc is divided into various divisions to provide optimal support for each researcher. The extensive range of products and services includes both hardware and software solutions for tissue and cell imaging. One of Akoya Biosciences Inc's core competencies is multiplex imaging technology, which allows researchers to simultaneously analyze multiple proteins in a sample. With Akoya Biosciences' Codex (Cyclic Immunofluorescence) System, up to 50 proteins can be detected in a tissue sample. This technology offers higher resolution and sensitivity, enabling faster and more precise research. Another division of Akoya Biosciences Inc is quantitative histology and biomarker development. The company offers a comprehensive range of innovative tools and unique technologies that support biomarker discovery and therapy development. These technologies enable better analysis of tissue samples and facilitate the identification of potential target molecules. The company also offers products for automated tissue processing, including the Tissue-Tek AutoSection Automated Microtome. This device allows for fast and precise sample processing, speeding up workflow in research. By using automated workflows, the efficiency and accuracy of analysis are improved. In addition to hardware solutions, Akoya Biosciences also provides software tools specifically designed for data analysis. With Akoya Biosciences' Phenoptics software suite, researchers can analyze multiple images simultaneously to quickly and easily collect and interpret data. The software allows for the identification of relevant molecules and visualizes their distribution in the samples. Overall, Akoya Biosciences offers a fully integrated ecosystem for tissue multiplex analysis, covering all aspects of research from sample preparation to data analysis. Through close collaboration with international research institutes and academies, the company stays up-to-date with the latest research and is able to anticipate the latest trends and developments. In summary, Akoya Biosciences Inc's business model is focused on providing cutting-edge researchers and scientists with innovative technologies and solutions to advance the discovery and development of novel therapies. Akoya Biosciences is a valuable partner for academics, pharmaceutical and biotech companies worldwide who utilize innovative tools to better understand diseases and develop new therapies.

Akoya Biosciences izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Akoya Biosciences vai uzņēmums nedod dividendes.

Akoya Biosciences ISIN ir US00974H1041.

Akoya Biosciences simbols ir AKYA.

Pēdējo 12 mēnešu laikā Akoya Biosciences maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Akoya Biosciences plāno maksāt dividendes 0 USD apmērā.

Akoya Biosciences pašreizējā dividendu rentabilitāte ir .

Akoya Biosciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Akoya Biosciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Akoya Biosciences tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Akoya Biosciences apmērā 0 USD, kas tika izmaksāta 5.12.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 5.12.2024..

Pēdējās dividendes izmaksa notika 5.12.2024..

Gadā 2023, Akoya Biosciences izmaksāja 0 USD dividendes.

Akoya Biosciences dividendes tiek izmaksātas USD.